Orbit Discovery
Generated by Meeveem AI
"Discovering peptide therapeutics through advanced high-throughput screening platforms"
Oxford
•11 - 50 Employees
•Biotechnology
About Orbit Discovery
Orbit Discovery develops peptide-based drugs for chronic diseases using an advanced screening platform. The company combines bead-based display technology with microfluidics to screen large chemical spaces and identify high-affinity peptide candidates. Services cover radionuclide delivery, nucleic acid targeting, protein degradation, and GPCR modulation for pharma partners and biotechs. The technology enables both affinity and functional screening of peptides. Using proprietary reporter cell lines and flow cytometry, Orbit Discovery screens linear and macrocyclic peptides against soluble and cell surface targets, delivering validated hits with strong binding profiles and biological activity.
31
Team Members
2015
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A future where peptide therapeutics precisely target diseases at the molecular level, delivering treatments that combine the specificity of biologics with the versatility of small molecules for previously undruggable targets.
Our Mission
At Orbit Discovery, our mission is to help partners identify peptide therapeutic hits through advanced high-throughput affinity and functional screening techniques.